Aktis Oncology filed for an initial public offering to raise capital for clinical development of its miniprotein radioconjugates, including a Nectin‑4‑targeted lead program in phase 1b. The company has drawn strategic investments and partnerships from Eli Lilly, Merck, Novartis and Bristol Myers Squibb and raised roughly $346 million in private financing prior to the filing. Aktis intends to use proceeds to fund ongoing dose‑escalation studies and advance a second asset into phase 1b, while bolstering imaging and patient‑selection capabilities. The filing reflects renewed investor interest in radiopharmaceuticals and alpha‑emitter approaches. Market participants will watch early clinical readouts expected in coming quarters as a test of investor appetite for biotech IPOs in 2026 and of radioconjugates’ clinical differentiation versus established ADCs and beta‑emitters.